Recursion Presents Phase 2 REC-4881 Data in FAP
The company said the data showed deep, durable polyp burden reductions, with activity across the GI tract and in larger, higher-risk polyps.
The company said the data showed deep, durable polyp burden reductions, with activity across the GI tract and in larger, higher-risk polyps.